Stock listing

NASDAQ:GCTK GlucoTrack, Inc. Stock

Home listing (NASDAQ) of GlucoTrack, Inc.

Follow GlucoTrack, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:GCTK

$0.183 USD -0.004 (-2.0%)

Close on Nov 20, 2026

Past year -99.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.183 – $0.200 USDNov 20, 2026
Volume
10,329 sharesNov 20, 2026
Market cap
$217,049 USDAt the close on Nov 20, 2026 · price × 1.18M shares outstanding
52-week range
$0.183 – $207.000 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.58M USDMedian day 25,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
GlucoTrack, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GCTK · Home$0.183 USD-0.004 (-2.0%)10,329$0.187$0.200$0.183$0.187Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GCTK · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.183-0.004-2.0%$0.187$0.200$0.18310,329
$0.1870.0000.0%$0.187$0.187$0.187403
$0.187-0.003-1.6%$0.187$0.187$0.1872,237
$0.190-0.027-12.4%$0.210$0.230$0.1907,554
$0.217-0.023-9.7%$0.240$0.240$0.2177,384
$0.240-0.040-14.3%$0.270$0.290$0.22711,724
$0.2800.0000.0%$0.280$0.340$0.28011,227
$0.2800.0000.0%$0.280$0.370$0.28013,923
$0.280-0.020-6.7%$0.280$0.340$0.2804,830
$0.300-0.080-21.1%$0.380$0.380$0.30041,300
$0.380-0.020-5.0%$0.400$0.420$0.36539,100
$0.400-0.058-12.7%$0.400$0.465$0.40020,300
$0.458-0.032-6.5%$0.487$0.487$0.342110,500
$0.490-0.320-39.5%$0.760$0.760$0.490132,400
$0.810-0.580-41.7%$0.530$0.910$0.500553,100
$1.390-0.660-32.2%$2.000$2.240$1.0705,470,200
$2.050+0.340+19.9%$2.000$2.500$1.80028,294,200
$1.710+0.100+6.2%$1.530$1.760$1.2904,718,200
$1.610+0.804+99.8%$0.840$1.760$0.77734,499,300
$0.806-0.392-32.7%$1.180$1.240$0.746180,700
$1.198-0.080-6.3%$1.218$1.310$1.12036,175
$1.278-0.024-1.8%$1.324$1.350$1.25418,550
$1.302-0.068-5.0%$1.354$1.356$1.18012,700
$1.370-0.080-5.5%$1.476$1.476$1.36425,700
$1.450-0.214-12.9%$1.680$1.680$1.40836,100
$1.664-0.110-6.2%$1.760$1.760$1.52038,450
$1.774-0.446-20.1%$2.200$2.200$1.72288,575
$2.220-0.100-4.3%$2.320$2.320$2.14040,525
$2.320+0.260+12.6%$2.180$2.400$2.08078,925
$2.060-0.160-7.2%$2.240$2.240$2.00058,950
$2.220-0.080-3.5%$2.240$2.420$2.16052,150
$2.300+0.040+1.8%$2.240$2.320$2.20024,300
$2.260+0.040+1.8%$2.240$2.280$2.14042,000
$2.220-0.200-8.3%$2.320$2.404$2.18058,200
$2.420-0.400-14.2%$2.680$2.680$2.30073,300
$2.820-0.460-14.0%$3.280$3.280$2.760158,525
$3.280-0.200-5.7%$3.580$3.640$3.020293,075
$3.480-0.120-3.3%$3.440$3.700$3.14066,200
$3.600-0.040-1.1%$3.680$3.900$3.560129,925
$3.640-1.520-29.5%$4.620$4.720$3.540505,850
$5.160+1.100+27.1%$4.860$6.500$4.76012,900,075
$4.060-0.380-8.6%$4.460$4.540$3.9966,894,675
$4.440-0.160-3.5%$4.440$4.620$4.420135,000
$4.600-0.340-6.9%$5.020$5.020$4.4209,675
$4.940+0.180+3.8%$4.780$5.100$4.7806,925
$4.760+0.270+6.0%$4.560$4.800$4.4804,675
$4.490-0.050-1.1%$4.500$4.680$4.36015,125
$4.540-0.360-7.3%$4.820$4.820$4.44014,150
$4.900-0.200-3.9%$5.000$5.340$4.62037,925
$5.100-1.360-21.1%$6.120$6.120$4.520185,425
$6.460+0.180+2.9%$6.080$6.460$6.0804,350
$6.280+0.420+7.2%$5.860$6.600$5.86014,725
$5.860-0.100-1.7%$6.060$6.220$5.8008,925
$5.960-0.680-10.2%$6.520$6.620$5.90018,050
$6.640-0.420-5.9%$7.120$7.292$6.58011,875
$7.060-0.300-4.1%$6.980$7.960$6.98014,925
$7.360-1.140-13.4%$8.160$8.540$7.35019,375
$8.500+0.040+0.5%$8.400$8.720$8.00038,275
$8.460-0.120-1.4%$8.400$8.670$8.3702,978
$8.580-1.050-10.9%$10.050$10.050$8.4901,881
$9.630-0.570-5.6%$10.320$10.500$9.450634
$10.200+0.240+2.4%$10.200$10.200$9.900621
$9.960-0.450-4.3%$10.110$10.350$9.900245
$10.410+0.150+1.5%$10.140$11.100$9.900767
$10.260-0.210-2.0%$10.410$10.500$9.900592

Splits

6 splits since 2021 · NASDAQ:GCTK · every price before a split is adjusted for it

DayRatioWhat
1-for-2Consolidation
1-for-15Consolidation
1-for-60Consolidation
1-for-20Consolidation
1-for-5Consolidation
1-for-13Consolidation
Ticker
NASDAQ:GCTK
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All GlucoTrack, Inc. news

GlucoTrack, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 108 in all · newest Oct 22, 2026 · oldest 2021
Decks
11 decks · latest Apr 30, 2026

Where GlucoTrack, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GCTK · Home listing · This pageNASDAQUnited StatesUSD
BOATS:GCTKBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
−$887,951 USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.73

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
GlucoTrack, Inc. · NASDAQ:GCTKUS$217,049−US$887,951n/an/an/an/an/an/a1.73
Jaguar Health, Inc. · NASDAQ:JAGXUS$527,406−US$1.48Mn/a−0.1×n/a0.0×−181.8%0.2×3.75
Altamira Therapeutics Ltd. · OTC:CYTOFUS$404,655US$400,900n/an/an/a0.1×n/a0.0×0.64
NKGen Biotech Inc. · OTC:NKGNUS$391,807US$38.58Mn/an/an/an/an/an/a0.88
Vaxil Bio Ltd. · TSXV:VXLUS$319,500−US$4,0701.2×n/an/a0.4×n/a0.0×-0.16
Chimeric Therapeutics Limited · ASX:CHMUS$292,816−US$220,193n/a−0.1×n/a0.2×−262.8%2.5×n/a
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
Regen BioPharma, Inc. · OTC:RGBPUS$167,528US$167,289n/a0.7×n/an/a−501.4%n/a1.20
CNBX Pharmaceuticals Inc. · OTC:CNBXUS$160,577US$151,090n/an/an/an/an/an/a1.78
Fifty 1 Labs Inc. · OTC:FITYUS$118,532US$282,021n/a6,000×n/an/an/an/a-1.17
Median of the othersUS$278,926US$73,5101.2×0.3×0.1×−262.8%0.0×1.14

Team and board

Officers

OfficerRole
Paul V. GoodePresident and Chief Executive Officer

Board

DirectorRole
Erin CarterChair of the Audit Committee

Events

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 12, 2026−22.6%
Q2 2026Aug 14, 2026−6.6%
Q3 2025Nov 13, 2025−12.6%
Q2 2025Aug 14, 2025−0.5%
Q1 2025May 14, 2025+2.7%
Q4 2024Mar 31, 2025+9.8%
Q4 2022Mar 31, 2023+15.4%
Q3 2022Nov 14, 2022−4.0%
Q2 2022Aug 15, 2022+8.4%
Q1 2022May 16, 2022+6.0%
All 14 quarters
QuarterResultsShare move
Q4 2021Mar 31, 2022−3.0%
Q3 2021Nov 15, 2021+2.6%
Quarter to Jun 30, 2021Aug 16, 2021−6.0%
Quarter to Mar 31, 2021Apr 13, 2021−20.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (April 2026)Investor deck23 slidesApr 30, 2026
Investor Presentation (April 2026)Investor deck23 slidesApril 2026
Investor Presentation (December 2025)Investor deck25 slidesDecember 2025
Investor Presentation (May 2025)Investor deck25 slidesMay 2025
Investor Presentation (February 2025)Investor deck17 slidesFebruary 2025
Investor Presentation (August 2024)Investor deck28 slidesAug 26, 2024
Investor Presentation (July 2024)Investor deck28 slidesJul 8, 2024
Investor Presentation (January 2024)Investor deck24 slidesJanuary 2024
Integrity Applications — Investor Presentation (November 2017)Investor deck22 slidesNov 3, 2017
Integrity Applications — Investor Presentation (October 2017)Investor deck16 slidesOct 5, 2017
All 11 decks
DeckKindSlidesDate
Integrity Applications — AMIZINO Fall 2013 Small Cap / Micro Cap Investment ConferenceConference28 slidesOct 29, 2013

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: about US$3.1M · US$2.04 a share · Dawson James Securities, Inc.
Dealers: Dawson James Securities, Inc. (lead)
Sep 24, 2026
Convertible notes with warrants
Announced: about US$11.5M · Warrants at US$7.5 · Dawson James Securities, Inc.
Dealers: Dawson James Securities, Inc. (lead)
Sep 11, 2026
Private placement of units
Announced: US$2M · US$0.75 a unit · Warrants at US$1.5 for 60 months · E.F. Hutton & Co.
Dealers: E.F. Hutton & Co.
Use of proceeds: Strengthen the balance sheet and provide additional growth capital
Aug 5, 2026
Convertible debt
Announced: US$3.5M · E.F. Hutton & Co.
Dealers: E.F. Hutton & Co.
Use of proceeds: Strengthen the balance sheet and provide additional growth capital
Aug 5, 2026
Bridge financing (securities not stated)
Closed: E.F. Hutton & Co.
Dealers: E.F. Hutton & Co. (lead)
Use of proceeds: Support strategic growth, including advancing the combined Glucotrack-Lokahi platform and other capital markets activities
Jul 17, 2026
Private placement of private placement financing (securities not stated)
Update: private placement
Use of proceeds: Strengthen the combined company's capital position and near-term execution; part to fund Glucotrack's legacy CBGM technology in a dedicated subsidiary
Jul 16, 2026
Private placement of shares of common stock (or common stock equivalents) and warrants
Announced: about US$4M · US$3.87 a share · Warrants at US$3.87 for 60 months · Curvature Securities LLC
Dealers: Curvature Securities LLC (lead)
Use of proceeds: Working capital and general corporate purposes
Dec 30, 2025
Common stock under equity purchase agreement
Update: US$20M
Buyers: Sixth Borough Capital Fund; Sixth Borough Capital Fund LP
Nov 3, 2025
Public offering of shares of common stock
Announced: about US$3M · US$1.15 a share · Dawson James Securities, Inc.
Dealers: Dawson James Securities, Inc. (lead)
Feb 4, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000070.8K208.0K17.0B589.5K611.7K
Cost of revenue36.0K13.0K23.0K42.0K47.0K51.0K95.6K140.2K59.6K
Gross profit-36.0K-13.0K-23.0K-42.0K-47.0K208.0K-52.1K449.3K552.1K
Research and development9.81M9.50M4.70M1.97M1.81M1.53M1.61M3.03M3.21M2.88M
Selling, general and administrative6.28M4.66M2.27M2.45M139.0K415.0K1.49M3.48M1.53M1.13M
Operating income-16.1M-14.5M-7.10M-4.43M-4.04M-3.13M3.51M-6.54M10.6M-5.66M
Depreciation and amortization42.0K36.0K13.0K23.0K32.0K32.0K51.0K58.8K67.9K59.6K
EBITDA-16.0M-14.5M-7.09M-4.41M-4.01M-3.10M3.56M-6.48M10.6M-5.60M
Interest expense44.0K03.00K4.16M98.0K10.0K18.3K24.4K16.2K
Income before tax-19.4M-22.6M-7.10M-4.43M-4.07M-2.70M-3.52M-6.72M-10.3M-5.41M
Income tax22.6M855.0K3.00K33.0K-98.0K43-13.2M24.4K16.2K
Net income-19.4M-22.6M-7.10M-4.43M-4.07M-2.70M3.52M-6.72M10.3M-5.41M
Earnings per share, basic31.224,106.0034.180.290.26-0.02-0.02-4.74-1.87-1.08
Earnings per share, diluted31.224,106.0034.180.290.260.19-0.02-4.74-1.87-1.08

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents7.38M5.62M4.49M2.31M6.06M9.82M419.0K97.1K53.8K148.8K
Receivables066.0K70.0K22.8K121.8K92.1K
Inventory0284.0K184.0K171.0K957.3K1.42M
Current assets7.67M5.77M4.87M2.38M6.11M10.2M718.0K314.1K1.23M2.02M
Property, plant and equipment138.0K95.0K27.0K40.0K69.0K149.0K134.0K149.8K216.7K240.5K
Total assets7.84M5.93M4.91M2.44M6.26M10.6M1.10M688.2K1.67M2.46M
Accounts payable1.32M992.0K839.0K672.0K631.0K869.0K1.53M2.06M2.42M1.63M
Current liabilities4.77M1.27M1.51M1.01M883.0K1.34M2.27M3.22M3.69M2.35M
Long-term debt231.0K203.0K196.0K195.0K210.0K197.0K190.4K168.2K
Total debt33.0K267.0K196.0K195.0K250.0K363.0K378.0K168.2K182.8K162.0K
Total liabilities5.01M18.9M1.71M1.21M1.11M1.62M2.51M3.56M4.82M3.37M
Shareholders' equity2.83M-13.0M3.20M1.23M5.16M8.98M-1.41M-2.87M-16.6M-10.9M
Shares outstanding910.7K13.4K208.9K15.5M15.5M15.4M161.9M141.6M6.82M6.03M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-15.2M-12.5M-6.56M-3.73M-3.77M-3.50M-3.90M-4.89M-5.90M-5.31M
Capital spending-96.0K-104.0K0-1.00K-5.00K-53.0K-23.0K-5.37K-19.5K-76.5K
Free cash flow-15.3M-12.6M-6.56M-3.73M-3.77M-3.55M-3.92M-4.90M-5.91M-5.39M
Cash from investing-96.0K-104.0K1.00K-1.00K-53.0K-23.0K-5.37K-19.5K-76.5K
Cash from financing17.0M13.7M8.73M0013.0M4.20M4.96M5.75M4.94M
Dividends paid0-5.73K-13.5K
Change in cash1.76M1.13M2.17M-3.78M-3.77M9.41M326.0K56.3K-91.2K-459.9K

Open Financials

Filings

FilingDateTypeFiled with
NT 10-Q · Late filing noticeNov 16, 2026Explanation requestSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2026Big-stake noticeSEC
8-K · Current reportOct 29, 2026Current reportSEC
8-K · Current reportOct 28, 2026Current reportSEC
8-K · Current reportOct 22, 2026Material contractSEC
8-K · Current reportOct 19, 2026Material contractSEC
PRE 14A · Preliminary proxy statementOct 14, 2026Meeting noticeSEC
S-1/A · Registration statement, amendedOct 13, 2026Offer documentSEC
425Oct 13, 2026Other filingsSEC
8-K/A · Current report, amendedOct 13, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 28, 2026Material contractSEC
424B5 · ProspectusSep 24, 2026Offer documentSEC
8-K · Current reportSep 24, 2026Material contractSEC
425Sep 23, 2026Other filingsSEC
8-K · Current reportSep 23, 2026Current reportSEC
8-K · Current reportSep 18, 2026Management or board changeSEC
S-1 · Registration statementSep 17, 2026Offer documentSEC
8-K · Current reportSep 14, 2026Material contractSEC
8-K · Current reportSep 11, 2026Material contractSEC
8-K · Current reportSep 9, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeSep 2, 2026Big-stake noticeSEC
8-K · Current reportAug 28, 2026Current reportSEC
425Aug 28, 2026Other filingsSEC
8-K/A · Current report, amendedAug 28, 2026Acquisition or disposalSEC
8-K · Current reportAug 27, 2026Current reportSEC
DEFA14A · Additional proxy materialAug 21, 2026Meeting noticeSEC
8-K · Current reportAug 19, 2026Meeting outcomeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
DEF 14A · Proxy statementAug 10, 2026Meeting noticeSEC
8-K · Current reportAug 10, 2026Material contractSEC
8-K · Current reportAug 5, 2026Material contractSEC
PRE 14A · Preliminary proxy statementJul 31, 2026Meeting noticeSEC
8-K · Current reportJul 30, 2026Current reportSEC
8-K/A · Current report, amendedJul 29, 2026Material contractSEC
8-K · Current reportJul 27, 2026Material contractSEC
DRS · Draft registration statementJul 24, 2026Offer documentSEC
ARS · Annual report to shareholdersJul 17, 2026Annual reportSEC
DEF 14A · Proxy statementJul 17, 2026Meeting noticeSEC
425Jul 15, 2026Other filingsSEC
8-K · Current reportJul 15, 2026Acquisition or disposalSEC
PRE 14A · Preliminary proxy statementJun 17, 2026Meeting noticeSEC
8-K · Current reportMay 15, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
8-K · Current reportMay 7, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMay 1, 2026Other filingsSEC
8-K · Current reportApr 30, 2026Material contractSEC
8-K · Current reportApr 30, 2026Current reportSEC
POS AM · Amendment to an effective registrationApr 29, 2026Offer documentSEC
8-K · Current reportApr 14, 2026Material contractSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 30, 2026ResultsSEC
8-K · Current reportMar 27, 2026Current reportSEC
8-K · Current reportMar 13, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
DEF 14A · Proxy statementFeb 9, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementJan 29, 2026Meeting noticeSEC
8-K · Current reportJan 29, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJan 28, 2026Other filingsSEC
424B3 · ProspectusJan 27, 2026Offer documentSEC
UPLOAD · Letter from the SECJan 27, 2026Other filingsSEC
CORRESP · Letter to the SECJan 23, 2026Other filingsSEC
S-3 · Registration statementJan 13, 2026Offer documentSEC
8-K · Current reportDec 31, 2025Material contractSEC
8-K · Current reportDec 29, 2025Current reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialNov 7, 2025Meeting noticeSEC
8-K · Current reportNov 7, 2025Meeting outcomeSEC
8-K · Current reportNov 6, 2025Meeting outcomeSEC
DEFA14A · Additional proxy materialNov 3, 2025Meeting noticeSEC
8-K · Current reportNov 3, 2025Current reportSEC
DEFA14A · Additional proxy materialOct 31, 2025Meeting noticeSEC
424B3 · ProspectusOct 30, 2025Offer documentSEC
8-K · Current reportOct 29, 2025Current reportSEC
DEFA14A · Additional proxy materialOct 28, 2025Meeting noticeSEC
8-K · Current reportOct 28, 2025Current reportSEC
DEFA14A · Additional proxy materialOct 15, 2025Meeting noticeSEC
S-1/A · Registration statement, amendedOct 8, 2025Offer documentSEC
3 · Initial statement of ownershipOct 7, 2025Insider tradeSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
DEF 14A · Proxy statementOct 3, 2025Meeting noticeSEC
S-1 · Registration statementSep 29, 2025Offer documentSEC
PRE 14A · Preliminary proxy statementSep 23, 2025Meeting noticeSEC
8-K · Current reportSep 12, 2025Material contractSEC
8-K · Current reportSep 11, 2025Material contractSEC
S-8 · Registration statement for employee plansSep 5, 2025Offer documentSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
8-K · Current reportAug 6, 2025Current reportSEC
8-K · Current reportJul 31, 2025Current reportSEC
8-K/A · Current report, amendedJul 25, 2025Current reportSEC
8-K · Current reportJul 24, 2025Current reportSEC
8-K · Current reportJul 8, 2025Current reportSEC
8-K · Current reportJun 25, 2025Current reportSEC
8-K · Current reportJun 16, 2025Current reportSEC
8-K · Current reportJun 12, 2025Current reportSEC
8-K · Current reportJun 4, 2025Current reportSEC
8-K · Current reportMay 23, 2025Management or board changeSEC
8-K · Current reportMay 20, 2025Current reportSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
8-K · Current reportMay 13, 2025Current reportSEC
8-K · Current reportApr 29, 2025Current reportSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 18, 2025Meeting noticeSEC
8-K · Current reportApr 16, 2025Current reportSEC
8-K · Current reportApr 4, 2025Current reportSEC
8-K · Current reportApr 3, 2025Current reportSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 28, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 28, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 28, 2025Insider tradeSEC
8-K · Current reportMar 19, 2025Current reportSEC
8-K · Current reportMar 13, 2025FinancingSEC
8-K · Current reportFeb 26, 2025Current reportSEC
8-K · Current reportFeb 14, 2025Current reportSEC
3 · Initial statement of ownershipFeb 7, 2025Insider tradeSEC
424B5 · ProspectusFeb 5, 2025Offer documentSEC
8-K · Current reportFeb 5, 2025Material contractSEC
8-K · Current reportFeb 4, 2025Current reportSEC
8-K · Current reportJan 30, 2025Current reportSEC
8-K · Current reportJan 29, 2025Management or board changeSEC
8-K · Current reportJan 21, 2025Current reportSEC
8-K/A · Current report, amendedJan 14, 2025FinancingSEC
8-K · Current reportJan 13, 2025FinancingSEC
8-K · Current reportJan 7, 2025Current reportSEC
8-K · Current reportJan 7, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 3, 2025Big-stake noticeSEC
8-K · Current reportDec 31, 2024Current reportSEC
424B5 · ProspectusDec 17, 2024Offer documentSEC
8-K · Current reportDec 17, 2024Material contractSEC
DEF 14A · Proxy statementDec 6, 2024Meeting noticeSEC
8-K · Current reportDec 3, 2024Current reportSEC
PRE 14A · Preliminary proxy statementNov 22, 2024Meeting noticeSEC
3 · Initial statement of ownershipNov 22, 2024Insider tradeSEC
8-K · Current reportNov 18, 2024Material contractSEC
8-K · Current reportNov 14, 2024Material contractSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
424B4 · ProspectusNov 14, 2024Offer documentSEC
8-K · Current reportNov 13, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveNov 13, 2024Other filingsSEC
CORRESP · Letter to the SECNov 12, 2024Other filingsSEC
CORRESP · Letter to the SECNov 12, 2024Other filingsSEC
S-1/A · Registration statement, amendedNov 8, 2024Offer documentSEC
S-1/A · Registration statement, amendedNov 8, 2024Offer documentSEC
S-1/A · Registration statement, amendedNov 4, 2024Offer documentSEC
S-1/A · Registration statement, amendedOct 24, 2024Offer documentSEC
8-K · Current reportOct 22, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveOct 4, 2024Other filingsSEC
8-K · Current reportOct 1, 2024Current reportSEC
CORRESP · Letter to the SECOct 1, 2024Other filingsSEC
S-3/A · Registration statement, amendedSep 30, 2024Offer documentSEC
UPLOAD · Letter from the SECSep 27, 2024Other filingsSEC
8-K · Current reportSep 26, 2024Meeting outcomeSEC
S-3 · Registration statementSep 23, 2024Offer documentSEC
S-1 · Registration statementSep 16, 2024Offer documentSEC
8-K · Current reportSep 10, 2024FinancingSEC
SC 13G · Big-stake noticeSep 10, 2024Big-stake noticeSEC
8-K · Current reportSep 3, 2024Management or board changeSEC
8-K · Current reportAug 27, 2024Current reportSEC
DEF 14A · Proxy statementAug 19, 2024Meeting noticeSEC
S-8 · Registration statement for employee plansAug 16, 2024Offer documentSEC
8-K · Current reportAug 15, 2024Current reportSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
PRE 14A · Preliminary proxy statementAug 9, 2024Meeting noticeSEC
8-K · Current reportAug 5, 2024Current reportSEC
8-K · Current reportJul 31, 2024Material contractSEC
8-K · Current reportJul 22, 2024Material contractSEC
8-K · Current reportJul 8, 2024Current reportSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
8-K · Current reportJul 1, 2024Material contractSEC
8-K · Current reportJun 20, 2024Management or board changeSEC
8-K · Current reportJun 13, 2024Current reportSEC
8-K · Current reportMay 24, 2024Current reportSEC
8-K · Current reportMay 20, 2024Current reportSEC
8-K · Current reportMay 16, 2024Current reportSEC
8-K · Current reportMay 15, 2024Current reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
DMay 8, 2024Other filingsSEC
8-K · Current reportMay 2, 2024Meeting outcomeSEC
3 · Initial statement of ownershipApr 24, 2024Insider tradeSEC
4 · Change in ownershipApr 24, 2024Insider tradeSEC
DEF 14A · Proxy statementApr 1, 2024Meeting noticeSEC

This page holds 200 of 497 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from GlucoTrack, Inc.’s releases · as of Sep 24, 2026

Common shares
1,184,119
Fully diluted
1,184,119

Fully diluted

LineShares
Common shares1,184,119

Share count over time

CountShares
Nov 22, 20261,184,119
Oct 22, 2026
Aug 27, 2026

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund33,2550.31%US$21,948May 31, 2026
Fidelity Series Total Market Index Fund450<0.01%US$297May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James S Cardwell
Other companies: Esports Entertainment Group, Inc. (Interim CFO · Feb 20, 2020 – Feb 20, 2020 · Past); VerifyMe, Inc. (Chief Financial Officer · Jan 11, 2018 – Jan 11, 2018 · Past)
Chief Financial Officer · Oct 11, 2023 – Oct 11, 2023 · Past
Peter C. Wulff
Other companies: PURE Bioscience (CFO, COO & Secretary · Nov 5, 2012 – Oct 23, 2013 · Past); Alphatec Holdings, Inc. (CFO, VP and Treasurer · Jun 16, 2008 – Aug 10, 2010 · Past)
Chief Financial Officer · Jan 28, 2025 – Nov 5, 2026 · Past
Brendel Victoria Carr
Other companies: Vicarious Surgical, Inc. (Director · Jan 23, 2023 – Jun 10, 2024 · Past)
Director · May 22, 2025 – May 22, 2025 · Past
Allen DanzigDirector · Mar 28, 2025 – Mar 28, 2025 · Past
Avner GalChairman and CEO, Director · Aug 14, 2012 – Mar 11, 2015 · Past
david podwalskiChief Commercial Officer · Jun 26, 2017 – Jun 26, 2017 · Past
Drew SycoffDirector · Apr 22, 2024 – Jul 1, 2024 · Past
Erin CarterChair of the Audit Committee · Since at least Aug 25, 2023
John A GrahamChief Executive Officer, Director · Mar 20, 2017 – Mar 20, 2017 · Past
John BallantyneDirector · Jul 30, 2024 – Aug 16, 2024 · Past
All 16 people
PersonSeat
Leslie SeffDirector · Mar 23, 2016 – Jun 1, 2017 · Past
Luis MalaveDirector · Mar 25, 2025 – Mar 31, 2025 · Past
Paul V. GoodePresident and Chief Executive Officer · Since at least Apr 22, 2024
Robert FischellDirector · Aug 14, 2012 – Mar 28, 2025 · Past
Sami SassounChief Financial Officer · Jan 31, 2017 – Jan 31, 2017 · Past
Zvi CohenDirector · Aug 14, 2012 – Mar 11, 2015 · Past

Open People

Log in to ask 6ix AI your own questions about GlucoTrack, Inc.